Takeda Pharm Stock Price, News & Analysis

Takeda Pharmaceutical Company (TSE:4502/NYSE:TAK) announced it will present 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021 in Atlanta, Georgia. The presentations focus on advancing treatments in oncology and hematology, featuring pipeline candidates like Modakafusp Alfa (TAK-573) and Subasumstat (TAK-981). A key highlight includes updates on TAK-755, a novel therapy for Sickle Cell Disease and Congenital Thrombotic Thrombocytopenic Purpura.

Takeda Pharmaceutical Company announced the U.S. launch of LIVTENCITY™ (maribavir), the first treatment for post-transplant cytomegalovirus (CMV) infection/disease resistant to conventional antivirals. Available since December 2, 2021, after receiving FDA approval on November 23, LIVTENCITY is designed for patients aged 12 and over weighing at least 35 kg. With an estimated incidence rate of 16%-70% in transplant recipients, CMV poses serious health risks, emphasizing the need for effective treatments. LIVTENCITY offers a new option for clinicians in managing this complex infection.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced a $20 million commitment to enhance its Corporate Social Responsibility (CSR) program in the U.S. during its first year. The program focuses on health equity, climate resiliency, K-8 math literacy, and food security, partnering with 20 grant recipients who will share $16.6 million in total grants. The initiative aims to alleviate social disparities and improve overall community well-being across various sectors.

Takeda Pharmaceutical Company Limited announced FDA approval for LIVTENCITY™ (maribavir), the first treatment for adults and pediatric patients (12 years and older) with post-transplant cytomegalovirus (CMV) infection refractory to conventional therapies. In the Phase 3 SOLSTICE study, 56% of patients on LIVTENCITY achieved CMV DNA levels

Takeda Pharmaceutical Company Limited (NYSE: TAK) has announced new policy recommendations aimed at improving care for patients with rare diseases. This initiative includes three primary reforms focused on enhancing access to genetic screenings and specialized care, as well as improving data standardization. A recent Morning Consult survey revealed that two-thirds of voters lack understanding of rare diseases, emphasizing the need for greater awareness. Takeda's report aims to address significant barriers to timely diagnoses and treatment, which currently average six years from symptom onset.

Takeda Pharmaceutical Company applied for selection to the Prime Market of the Tokyo Stock Exchange (TSE). The decision was made during the Board of Directors Meeting on September 29-30, 2021, following the TSE's initial assessment on July 9, 2021, confirming compliance with listing requirements. The company also submitted its Corporate Governance Report based on an updated governance code. Enhancements to governance transparency include updated documents available on its corporate website. This move aims to maximize corporate value and strengthen stakeholder engagement.

Takeda Pharmaceutical Company announced a share buyback plan of up to 100 billion yen, aiming to acquire up to 35 million shares, representing 2.23% of outstanding shares. The initiative is designed to enhance capital efficiency and improve shareholder returns, indicating confidence in the company's cash generation capabilities. The buyback is scheduled from November 2, 2021 to April 29, 2022 and will not affect Takeda's existing deleveraging goals. The company's strong pipeline includes approximately 40 new molecular entities.

Takeda Pharmaceutical Company (NYSE:TAK) reported impressive financial results for H1 FY2021, with a 12.8% increase in reported revenue, amounting to 1,794.4 billion yen ($16.1B), and a 6.8% rise in underlying revenue of 1,661.4 billion yen ($14.9B). The company confirmed its full-year guidance aiming for a 30% core operating profit margin. Further growth is expected through its 14 global brands, which contributed 42% of total core revenue, and a share buyback of up to 100 billion yen highlights confidence in business strategy.

Takeda Pharmaceutical Company has announced its acquisition of GammaDelta Therapeutics, a biotech focused on γδ T cell immunotherapy. This strategic move expands Takeda's capabilities in the immuno-oncology space, targeting solid tumors and blood cancers. The acquisition follows a successful collaboration established in 2017 and involves pre-negotiated upfront and milestone payments. With a focus on off-the-shelf therapies, Takeda aims to enhance patient access to innovative cancer treatments. The deal is set to finalize in Q1 of Takeda's fiscal year 2022, pending regulatory review.